当前位置: 首页 > 期刊 > 《医药产业资讯》 > 2019年第12期
编号:13343420
hnRNPA2/B1在恶性肿瘤中的研究进展(5)
http://www.100md.com 2019年4月25日 《中国医药导报》 2019年第12期
     [25] Wang H,Liang L,Dong Q,et al. Long noncoding RNA miR503HG,a prognostic indicator,inhibits tumor metastasis by regulating the HNRNPA2B1/NF-κB pathway in hepatocellular carcinoma [J]. Theranostics,2018:2814-2829.

    [26] Deng J,Song C,Feng W,et al. Effects of hnRNP A2/B1 Knockdown on Inhibition of Glioblastoma Cell Invasion,Growth and Survival [J]. Mol Neurobiol,2016,53(2):1132-1144.

    [27] Dai P,Wang Q,Wang W,et al. Unraveling Molecular Differences of Gastric Cancer by Label-Free Quantitative Proteomics Analysis [J]. Int J Mol Sci,2016,17(1):E69.

    [28] Jing GJ,Xu DH,Shi SL,et al. Aberrant expression and localization of hnRNP-A2/B1 is a common event in human gastric adenocarcinoma [J]. J Gastroenterol Hepatol,2011,26(1):108-115.

    [29] Shi X,Ran L,Liu Y,et al. Knockdown of hnRNP A2/B1 inhibits cell proliferation,invasion and cell cycle triggering apoptosis in cervical cancer via PI3K/AKT signaling pathway [J]. Oncol Rep,2018,39(3):939-950.

    (收稿日期:2018-10-25 本文編辑:金 虹), http://www.100md.com(刘雅雯 张尤历 徐岷)
上一页1 2 3 4 5